Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen, Roche hematology news

The U.S. District Court for the District of Massachusetts granted AMGN's motion for summary judgment and ruled that ROG's Mircera methoxy polyethylene glycol-epoetin beta would infringe AMGN's U.S. Patent

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE